Helmholtz Munich’s Post

⚗️ Unveiling the Promise of Molecular Glues in Pharma! 💡 Molecular glues: a term that's igniting excitement across pharma circles. But what exactly are these innovative compounds? 🔍 Since the 1990s, molecular glues have staked their claim in pharma research, particularly in oncology and rare diseases. These minuscule molecules have a knack for inducing targeted protein degradation (TPD), reshaping proteins and directing enzymes for therapeutic precision 💊 Artificial intelligence could be the catalyst for a molecular glue gold rush. With AI, discoveries give way to engineered searches through vast molecular landscapes. Bristol Myers Squibb's hefty investment in AI-based molecular glue innovation is just a taste of what's brewing 💻 The horizon for molecular glues stretches far and wide. Stay tuned, the pharmaceutical frontier is evolving 🚀 #MolecularGlues #TargetedProteinDegradation #Oncology #RareDisease #PharmaInnovation #DrugDiscovery #ClinicalResearch #LifeScience #ElixirAssociates #StaffingPartner

#Webinar Alert: join us next week to learn about a revolutionary discovery #proteomics approach that is enabling deep interrogation of the human #proteome at speed, scale, and with high analytical specificity. See how this #massspectrometry-based method captures biologically important proteins and is being applied to rapidly advance #clinical biomarkers in drug development programs today. Register here: https://bit.ly/3PutCVM

#Webinar Alert: join us next week to learn about a revolutionary discovery #proteomics approach that is enabling deep interrogation of the human #proteome at speed, scale, and with high analytical specificity. See how this #massspectrometry-based method captures biologically important proteins and is being applied to rapidly advance #clinical biomarkers in drug development programs today. Register here: https://bit.ly/3TLVxmP

What if a patient's own immune cells could produce therapeutics 𝘪𝘯𝘴𝘪𝘥𝘦 𝘵𝘩𝘦 𝘣𝘰𝘥𝘺? With promising early insights from the first-ever clinical trial of engineered B cell therapies, we're getting closer to finding out. 𝐒𝐭𝐨𝐫𝐲 𝐚𝐭 𝐚 𝐆𝐥𝐚𝐧𝐜𝐞: 🔬 Researchers are creating B cell "biofactories" that express therapeutic proteins within patients' bodies, aiming to develop safe and more efficient treatments. ⚕ Designed to treat a rare fatal genetic condition called MPS I, Immusoft's lead technology has been administered to the first human patient. 💊 Early readouts of the Phase I human clinical trial show excellent safety and pharmacodynamic effects, per Immusoft CEO Sean Ainsworth. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 Springer Nature Group 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐟𝐫𝐨𝐦 Cormac Sheridan: https://lnkd.in/embsZb4V

Just because you can run whole transcriptome and exome sequencing in your clinical trial doesn't mean you should. Many biomarkers in omics tests are not reproducible, or not at the prevalence to make a suitable biomarker. Do the digging in a preclinical setting, not in the clinic. #biomarkers #drugdevelopment

The Spatial Biology for Drug Development Summit starts tomorrow. Meet with us there to learn how we can assist in all aspects of #biomarker research, from discovering new biomarkers to the development and support of their clinical use. https://hubs.la/Q023sHf50 #SpatialBiology

Budgeting outsourcing for 2024 for projects involving neural models? Keep Axol Bioscience Ltd. in mind and let me know how we can help. We are human iPSC (hiPSC) experts operating to support drug discovery, with a special focus in neurodegenerative/inflammatory diseases. We offer specialist hiPSC related services all the way from material sourcing through reprogramming and gene editing if required, differentiation to end point and at scale, and best-in-class manufacturing. We are specialists in platform integration (i.e., building hiPSCs into MPS/organ-on-chip, higher content platforms, etc.). We build disease models with hiPSCs with measurable endpoint assays to test compounds. Our cells are used to fuel many leading platform providers, biopharma companies, and large scale CROs. Whether you are east coast, west coast, or somewhere in between, I'm coming to you in 2023 to help plan for 2024! Book me now while timeslots are open. #drugdiscovery #hiPSCs #pharmaceuticals #neurodegenerativediseases

For more detail on this exciting AI-driven Drug Discovery, check out the episode and the BioTalk Unzipped podcast with Jason Burke, Chad Briscoe, and myself (link in the comments). #AI #DrugDiscovery

Attention all Macrophage Experts! 📢 If you're looking to learn from the past and 𝗽𝗿𝗼𝗽𝗲𝗹 𝘆𝗼𝘂𝗿 𝗺𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝘁𝗼 𝗰𝗹𝗶𝗻𝗶𝗰, look no further than the 𝟲𝘁𝗵 𝗠𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲-𝗗𝗶𝗿𝗲𝗰𝘁𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗦𝘂𝗺𝗺𝗶𝘁! 𝗙𝘂𝗹𝗹 𝗔𝗴𝗲𝗻𝗱𝗮 𝗛𝗲𝗿𝗲 ➡️ https://bit.ly/455dOQ7 𝗨𝗻𝗶𝘁𝗶𝗻𝗴 𝟲𝟬 𝗯𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗮𝗻𝗱 𝗮𝗰𝗮𝗱𝗲𝗺𝗶𝗮 𝗹𝗲𝗮𝗱𝗲𝗿𝘀 across R&D, discovery, biology, translational science, and clinical development, this is poised to be a must-attend event, deep-diving into the evolving macrophage-therapeutics landscape, exploring other indications, and tackling the most pressing industry challenges.💡 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝘁𝗵𝗲 𝗙𝘂𝗹𝗹 𝗣𝗿𝗼𝗴𝗿𝗮𝗺 ➡️ https://bit.ly/455dOQ7 This is an incredible opportunity to unlock the full potential of your own macrophage therapeutics, with insights from 𝗖𝗮𝗿𝗶𝘀𝗺𝗮 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, 𝗘𝗹𝗽𝗶𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀, 𝗝𝗼𝗵𝗻 𝗛𝗼𝗽𝗸𝗶𝗻𝘀 𝗦𝗰𝗵𝗼𝗼𝗹 𝗼𝗳 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲, 𝗔𝗟𝗫 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆, 𝗩𝗲𝗿𝘀𝗲𝗮𝘂 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, and many more!🔓 Book your seat at https://bit.ly/450Afpr before Friday to 𝘀𝗮𝘃𝗲 𝘂𝗽 𝘁𝗼 $𝟵𝟬𝟬, plus an 𝗮𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝟮𝟬% 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁 when you bring 5 or more colleagues, which will facilitate valuable collaborative learning within your team. #MacrophageDirectedTherapiesSummit

As a biophysicist you occasionally come across things that defy expectations. The interaction between interleukin-13 (IL-13) and one of its receptors, IL-13Ra2, is an example of one of these. This interaction is so tight that it is very difficult to characterise using normal techniques, and requires a careful approach, with specially designed assays, to investigate. The journal article below, published by LEO Pharma and including Surface Plasmon Resonance (SPR) data generated at Sygnature Discovery, is an example of how biophysical assays can be utilised to measure the most potent of interactions. In this example, a chaser assay was used to probe occupancy over very long time periods, leading to the estimation of a femtomolar affinity. It's always interesting to see how far a technology can be pushed and it’s great to see this data helping to develop the understanding of how therapeutics like Tralokinumab work. #biophysics #SPR #drugdiscovery #biacore https://lnkd.in/eirVHxW6